Peptide histidine isoleucine (PHI), peptide histidine valine (PHV), and vasoactive intestinal polypeptide (VIP) are cosynthesized from the same precursor and share high levels of structural similarities with overlapping biological functions. In this study, the first PHI/PHV receptor was isolated and characterized in goldfish. To study this receptor using homologous peptides, we have also characterized the goldfish prepro-PHI/VIP, and, surprisingly, a shorter transcript lacking the VIP coding region was isolated. A PHI/VIP precursor without the VIP coding sequence has never before been reported. peptide histidine isoleucine (PHI) are members of the pituitary adenylate cyclase-activating polypeptide (PACAP)/ glucagon family. These peptides share many structural and biological similarities. They are cosynthesized from a common precursor; colocalized in the central nervous, gastrointestinal, reproductive, and respiratory systems; and coreleased in response to stimulation (1-7). It is interesting to note that similar to PACAP-27 and PACAP-38, a C-terminally extended form of PHI, known as peptide histidine valine (PHV), is also present in high concentrations in the circulation (8), although the function of this peptide is still unclear.VIP and PHI mediate a number of similar physiological actions in many systems, but the potencies of PHI are one to three orders of magnitude lower than those of VIP in various studies (5, 9 -13). Thus, PHI has been considered a weak agonist for VIP. In the gastrointestinal system, they both augment water and electrolyte transport in the jejunum (9, 14) and glucagon release from the pancreas (15). In the neuroendocrine system, they stimulate the secretion of PRL in the pituitary (10) and increase melatonin synthesis in the pineal gland (12). In the reproductive system, both peptides inhibit fallopian smooth muscle activity (5). In the vascular system, they produce an increase in vertebral artery blood flow (13).The biological effects of VIP are mediated through at least two receptor subtypes, termed VPAC1-R (16) and VPAC2-R (17), that exhibit high affinity for both VIP and PACAP. A third receptor, termed PAC1-R, that possesses high affinity for PACAP but a much lower affinity for VIP has been characterized (18). Up to now, a selective PHI receptor has not been identified, and it was generally accepted that the effects of PHI were mediated through VIP receptors. As a matter of fact, there is evidence that PHI shares common receptors with VIP: 1) PHI has been reported to bind VIP-preferring sites in many preparations (19 -21); 2) maximal doses of PHI and VIP do not produce additive effects (5, 10 -13, 16); and 3) cross-desensitization of PHI and VIP has been demonstrated (11,12,21). Thus, it is likely that at least some of the actions of PHI are mediated by binding to VIP-preferring sites. However, there are examples indicating that the biological responses to PHI are distinct from those evoked by VIP: 1) PHI injection in the preoptic area of rats facilitates LH secretion, whereas VIP inj...